Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 17,950 Shares

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 17,950 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $18.13, for a total transaction of $325,433.50. Following the completion of the sale, the chief financial officer directly owned 169,259 shares of the company’s stock, valued at $3,068,665.67. This represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Stock Up 1.5%

Shares of OMDA traded up $0.28 during mid-day trading on Wednesday, hitting $18.58. 706,805 shares of the company’s stock were exchanged, compared to its average volume of 1,201,429. The stock has a market cap of $1.10 billion and a price-to-earnings ratio of -68.81. The firm has a fifty day moving average of $16.09 and a two-hundred day moving average of $14.79. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. The business had revenue of $78.05 million during the quarter. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. On average, equities analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

OMDA has been the topic of a number of research analyst reports. Canaccord Genuity Group set a $24.00 target price on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Omada Health in a report on Thursday, June 4th. Evercore reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Omada Health in a research report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. cut their price objective on Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.91.

Hedge Funds Weigh In On Omada Health

Large investors have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Omada Health during the fourth quarter valued at about $1,222,000. Divisadero Street Capital Management LP acquired a new stake in Omada Health during the third quarter worth about $30,510,000. a16z Perennial Management L.P. acquired a new stake in Omada Health during the fourth quarter worth about $2,480,000. Madryn Asset Management LP bought a new position in Omada Health during the fourth quarter valued at about $9,212,000. Finally, Independent Advisor Alliance acquired a new position in Omada Health in the 4th quarter valued at approximately $717,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.